Eledon Pharmaceuticals, Inc. Business Acquisition, Pro Forma Revenue
Eledon Pharmaceuticals, Inc. (ELDN) reported Business Acquisition, Pro Forma Revenue of $120.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-24.
Discontinued › Income Statement › Other Income
us-gaap:BusinessAcquisitionsProFormaRevenue · last filed 2022-03-24
- Eledon Pharmaceuticals, Inc. business acquisition, pro forma revenue for the quarter ending 2020-12-31 was $0.00, a 100.00% decline year-over-year.
- Eledon Pharmaceuticals, Inc. business acquisition, pro forma revenue for the quarter ending 2020-09-30 was $120.00K, a 52.00% decline year-over-year.
- Eledon Pharmaceuticals, Inc. business acquisition, pro forma revenue for the quarter ending 2019-12-31 was $250.00K.
- Eledon Pharmaceuticals, Inc. business acquisition, pro forma revenue for the quarter ending 2019-09-30 was $250.00K.
- Eledon Pharmaceuticals, Inc. business acquisition, pro forma revenue for fiscal 2020 was $120.00K, a 76.00% decline from fiscal 2019.
- Eledon Pharmaceuticals, Inc. business acquisition, pro forma revenue for fiscal 2019 was $500.00K.
| Period end | Business Acquisition, Pro Forma Revenue 3 month | Business Acquisition, Pro Forma Revenue 6 month | Business Acquisition, Pro Forma Revenue 9 month | Business Acquisition, Pro Forma Revenue 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | $120.00K derived: sum of 2 quarters · filed 2022-03-24 | $120.00K 10-K · filed 2022-03-24 | |
| 2020-09-30 | $120.00K 10-Q · filed 2021-11-12 | $120.00K 10-Q · filed 2021-11-12 | ||
| 2019-12-31 | $250.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $500.00K derived: sum of 2 quarters · filed 2021-03-31 | $500.00K 10-K · filed 2021-03-31 | |
| 2019-09-30 | $250.00K 10-Q · filed 2020-11-16 | $250.00K 10-Q · filed 2020-11-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |